

NEWS RELEASE

RECORDATI: PUBLIC DISCLOSURE

Milan, 18th December 2020 – Please be informed that the summary report of the voting results related to the resolutions approved by the Extraordinary Shareholders' Meeting on 17th December 2020, pursuant to article 125-quater of the Legislative Decree 58/98, is available to the public on the Company's website (www.recordati.it, in the area "Investors", section "Shareholders' Meetings – Reverse Merger into Recordati S.p.A. 2020/2021") and on the "1info" storage mechanism (www.1info.it).

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2019 was € 1,481.8 million, operating income was € 465.3 million and net income was € 368.9 million.

Media Relations

Studio Noris Morano

For further information:

Recordati website: www.recordati.com

Investor Relations
Marianne Tatschke
(39)0248787393
e-mail: investorelations@recordati.it

(39)0276004736, (39)0276004745 e-mail: norismorano@studionorismorano.com

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

FAX (39) 0240073747